lbl-024
Small moleculeexperimental
Clinical trial activity
7 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
7
Phase 3
0
Phase 4
0
Earliest trial started Jan 6, 2022 (NCT05170958)
Timeline
Indications
Mechanism of action
TNFRSF9 agonist
- Programmed cell death 1 ligand 1INHIBITOR
CD274 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07281976 | Phase 1/Phase 2 (Phase 2) | Dec 31, 2025 | Nanjing Leads Biolabs Co.,Ltd, Nanjing Medical University |
| NCT07042802 | Phase 1/Phase 2 (Phase 2) | Dec 10, 2025 | Chinese Academy of Medical Sciences, Nanjing Leads Biolabs Co.,Ltd |
| NCT07111546 | Phase 2 | Oct 20, 2025 | Fudan University, Nanjing Leads Biolabs Co.,Ltd |
| NCT07099430 | Phase 1/Phase 2 (Phase 2) | Sep 5, 2025 | Fujian Medical University, Nanjing Leads Biolabs Co.,Ltd |
| NCT06783647 | Phase 2 | Feb 15, 2025 | Nanjing Leads Biolabs Co.,Ltd, Sun Yat-Sen University |
| NCT06157827 | Phase 1/Phase 2 (Phase 2) | Dec 5, 2023 | Nanjing Leads Biolabs Co.,Ltd, Peking University |
| NCT05170958 | Phase 1/Phase 2 (Phase 2) | Jan 6, 2022 | Nanjing Leads Biolabs Co.,Ltd, Peking University |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Nanjing Leads Biolabs Co.,Ltd | For profit | 7 | 7 | 1 | 2022 |
| Peking University | Academic/Hospital | 2 | 0 | 1 | 2022 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Fudan University | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Fujian Medical University | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Nanjing Medical University | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Sun Yat-Sen University | Academic/Hospital | 1 | 0 | 1 | 2025 |
7 organizations
Page 1 / 1